Unity Biotechnology, Inc. (UBX)
NASDAQ: UBX · Real-Time Price · USD
0.1125
+0.0087 (8.38%)
At close: Jul 15, 2025
Unity Biotechnology Stock Forecast
UBX's stock price has decreased by -91.41% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover Unity Biotechnology stock have a consensus rating of "Strong Buy" and an average price target of $4.67, which forecasts a 4051.11% increase in the stock price over the next year. The lowest target is $2 and the highest is $8.
Price Target: $4.67 (+4051.11%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 27, 2025.
Analyst Ratings
The average analyst rating for Unity Biotechnology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $4 → $2 | Strong Buy → Hold | Downgrades | $4 → $2 | +1,677.78% | May 27, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +3,455.56% | Apr 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +3,455.56% | Apr 23, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $6 → $4 | Strong Buy | Maintains | $6 → $4 | +3,455.56% | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +3,455.56% | Mar 25, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
8.34M
EPS This Year
-1.47
from -1.54
EPS Next Year
-0.95
from -1.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 26.0M | 62.6M | ||
| Avg | n/a | 8.3M | 20.1M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 650.4% | ||
| Avg | - | - | 140.6% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.33 | -0.92 | -0.55 | ||
| Avg | -1.47 | -0.95 | -0.80 | ||
| Low | -1.60 | -0.98 | -1.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.